Cresco Labs (CRLBF) Income from Continuing Operations (2020 - 2026)
Cresco Labs' (CRLBF) quarterly Income from Continuing Operations came in at 11426000.0 in Q1 2026, down 14.72% YoY from 13398000.0 in Q1 2025, and up 113.39% on a QoQ basis from 85341000.0 in Q4 2025.
Cresco Labs (CRLBF) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Cresco Labs (CRLBF) has 7 years of Income from Continuing Operations data on file, last reported at 11426000.0 in Q1 2026.
- Quarterly Income from Continuing Operations fell 14.72% year-over-year to 11426000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 52770000.0 (down 382.13% YoY) and the FY2025 annual result came in at 140044000.0, down 131.52% from the prior year.
- Income from Continuing Operations advanced to 11426000.0 in Q1 2026, from 85341000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 38980000.0 in Q2 2022 to a low of 133101000.0 in Q4 2022.
- A 5-year average of 8943176.47 and a median of 11426000.0 in 2026 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations surged 498.53% — and 2025, when it slumped 1604.87%.
- Tracing CRLBF's Income from Continuing Operations over 5 years: stood at 133101000.0 in 2022, then surged by 115.6% to 20768000.0 in 2023, then slumped by 72.69% to 5671000.0 in 2024, then tumbled by 1604.87% to 85341000.0 in 2025, then jumped by 113.39% to 11426000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 11426000.0 (Q1 2026), 85341000.0 (Q4 2025), and 1766000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.76 Bn | 42.79 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.38 Bn | 39.73 Bn | 2.15 Bn | -576.00 Mn |
| 3 | Zoetis | 31.61 Bn | 29.93 Bn | 1.05 Bn | 866.00 Mn |
| 4 | Takeda Pharmaceutical | 28.64 Bn | 22.84 Bn | 5.10 Bn | 1.33 Bn |
| 5 | United Therapeutics | 22.20 Bn | 19.54 Bn | 683.80 Mn | 333.00 Mn |
| 6 | Viatris | 18.82 Bn | 17.93 Bn | 1.46 Bn | -118.80 Mn |
| 7 | Neurocrine Biosciences | 15.67 Bn | 15.28 Bn | 935.80 Mn | 144.40 Mn |
| 8 | Elanco Animal Health | 12.11 Bn | 11.58 Bn | 798.00 Mn | 54.00 Mn |
| 9 | Dr Reddys Laboratories | 10.10 Bn | 9.94 Bn | - | - |
| 10 | Cresco Labs | 291.27 Mn | 227.16 Mn | 86.95 Mn | -22.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 11.43 Mn |
| Dec 31, 2025 | -85.34 Mn |
| Sep 30, 2025 | 1.77 Mn |
| Jun 30, 2025 | 19.38 Mn |
| Mar 31, 2025 | 13.40 Mn |
| Dec 31, 2024 | 5.67 Mn |
| Sep 30, 2024 | 30.34 Mn |
| Jun 30, 2024 | -30.70 Mn |
| Mar 31, 2024 | 33.95 Mn |
| Dec 31, 2023 | 20.77 Mn |
| Sep 30, 2023 | -124.94 Mn |
| Jun 30, 2023 | -15.59 Mn |
| Mar 31, 2023 | 5.81 Mn |
| Dec 31, 2022 | -133.10 Mn |
| Sep 30, 2022 | 34.22 Mn |
| Jun 30, 2022 | 38.98 Mn |
| Mar 31, 2022 | 21.94 Mn |
| Dec 31, 2021 | 35.15 Mn |
| Sep 30, 2021 | -219.60 Mn |
| Jun 30, 2021 | 29.58 Mn |